-
2022CSH on the frontiers of blood, explore the future pattern! It is time to set sail and create brilliance with cohesion, and the 17th National Hematology Academic Conference of the Chinese Medical Association was grandly held!
Time of Update: 2022-10-01
Listening to the sound of blood and perceiving the rhythm of life, the "17th National Hematology Academic Conference of the Chinese Medical Association" hosted by the Chinese Medical Association and t
-
Professor Liu Tianshu: The ORR is as high as 42%, and the T-DXd second-line treatment of HER2+ advanced gastric cancer has begun to appear
Time of Update: 2022-10-01
How do you see the value of DG02 research in the breakthrough of HER2+ advanced GC second-line therapy?Professor Liu TianshuThe DG02 trial is an open-label, multicenter Phase II clinical study designed to evaluate the efficacy and safety of T-DXd in HER2+ advanced GC/GEJC with disease progression following trastuzumab therapy.
-
Concerned about cervical cancer Is it safe for Chinese women aged 26 years and older to receive the AS04-HPV-16/18 vaccine? Is the vaccine long-term effective after 18-25 years old?
Time of Update: 2022-10-01
The results of the Key Efficacy Study (HPV-039, NCT00779766) proved that within 6 years of the first vaccination, the three-dose AS04-HPV-16/18 vaccine was still effective for Chinese women aged 18 to 25 who had been vaccinated but had persistent infection with HPV-16/18 virus for 6 months and had grade 1 or higher cervical intraepithelial neoplasia (CIN1+), so it was approved for domestic introduction.
-
2022 ESMO | DESTINY-Gastric 02 Research Update: OS reaches 12.1 months, which is expected to establish a new pattern of second-line treatment of HER2-positive advanced gastric cancer
Time of Update: 2022-10-01
Among them, the DESTINY-Gastric02 study, which evaluated the effect of T-DXd in the second-line treatment of HER2-positive advanced gastric cancer, was featured in the ESMO "Mini Oral" session, publishing overall survival (OS), patient-reported outcomes (PRO) and updated safety data [1].
-
Rapid CAR-T cell therapy breaks new: quickly eliminate serious side effects and overcome tumor resistance
Time of Update: 2022-10-01
Preliminary results from the first human trial showed that this controlled CAR-T cell therapy not only showed a complete remission rate of 67% when treating B-cell blood cancer patients who had undergone multiple pre-treatments, but also shortened the duration of adverse reactions to 2-3 days, significantly shorter than approved CAR-T therapy (5-17 days).
-
Heavy! The first multi-center research project of lymphoma MRD monitoring with the participation of 15 units in China was officially launched
Time of Update: 2022-10-01
In recent years, with the widespread use of second-generation sequencing (NGS), the ability to detect minimal residual disease (MRD) in hematologic malignancies, especially leukemia and multiple myelo
-
JAMA Subjournal: Are Children More Likely to Have Cancer in Assisted Reproduction? The Chinese team found that children born through ART had a 58% increased risk of cancer in children
Time of Update: 2022-10-01
3 million three-person families across Taiwan found that compared with natural birth, the overall risk of childhood cancer in children conceived through ART increased by 58%, of which the risk of leukemia and liver tumors increased by 110% and 171%, respectively; And this increased risk is not mediated by preterm birth or low birth weight.
-
"The Lancet": Tobacco and alcohol are the number one carcinogenic "murderer" real hammer! Data from the largest global burden of disease study to date show that more than 40% of cancers are associated with preventable carcinogenic risk factors such as alcohol and tobacco
Time of Update: 2022-10-01
45 million cancer deaths worldwide can be attributed to carcinogenic risk factors such as smoking and alcohol consumption, which accounts for 44.
45 million cancer deaths worldwide can be attributed to carcinogenic risk factors such as smoking and alcohol consumption, which accounts for 44.
-
Case sharing | the successful treatment of metastatic kaposi's sarcoma by navullizumab
Time of Update: 2022-10-01
Kaposi's sarcoma (KS) is an angioproliferative malignancy associated with human herpes virus 8 (HHV-8) and is more common in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and chronic immunosuppressive states.
govTarget populationNumberTherapeutic drugsType of studyPhase II multicenter study of pabolizumab for the treatment of classic/endemic Kaposi's sarcoma (KAPKEY).
-
How many joys and how many sorrows? ESMO three major lung cancer new drug data released
Time of Update: 2022-10-01
(Figure 5 Most Common Adverse Events) CEMI's First 3-Year Survival Data Disease Progression Treatment Still Improves ▌ 3-Year Survival Rate in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) After Receiving CEMI Chemotherapy Summary No. LBA54 Compared with chemotherapy, for patients with newly diagnosed advanced NSCLC, CEMI monotherapy provides significant improvements in overall survival (OS) and acceptable safety.
-
The second deadliest cancer in the world! Doing 1 thing well reduces the risk of recurrence and death
Time of Update: 2022-10-01
According to a study published in the Journal of Clinical Oncology, more physical activity in patients with stage 3 colon cancer helped reduce the risk of recurrence and death, which is associated with a better prognosis, including disease-free survival (DFS) and overall survival (OS).
-
"Evidence-based" resection or retention? How would you choose the surgical regimen for patients with testicular germ cell tumors?
Time of Update: 2022-10-01
Editor: Wang MumuReviewer: LRExecution: LRIn some genitourinary cancers, organ retention surgery is the preferred treatment, but for patients with testicular germ cell tumors (TGCT), radical orchiectomy is the standard of care.
-
After the bone marrow transplant, the first question the patient asked me was... NEJM view
Time of Update: 2022-10-01
A resident of Brigham and Women's Hospital in the United States used his own childhood experience to fight cancer to understand the questions asked by his patients, and published in the "Opinions" column of the New England Journal of Medicine (NEJM).
-
Professor Paul DiSilvestro, | ESMO Global Perspective: There was significant improvement in the two-year maintenance treatment of BRCA-mutant patients with advanced ovarian cancer
Time of Update: 2022-10-01
At the ESMO conference, Professor Paul DiSilvestro reported the study's 7-year follow-up data, and the results showed that compared with placebo, Orapalil maintenance therapy for 2 years produced long-term overall survival (OS) benefits in patients with BRCA mutation advanced ovarian cancer (OC), while no new safety signals were detected, providing 。 Figure 1.
-
YouYOUNG good doctor voice fierce competition, each show style! Suwan Station advanced colorectal cancer cases are coming
Time of Update: 2022-10-01
*For medical professionals only"Excellent YOUNG good medical voice" Suwan station wonderful case speech hit hard!Colorectal cancer (CRC) seriously endangers the health of Chinese residents, and advanc
-
Lancet Sub-Journal People with diabetes are at higher risk of developing pancreatic cancer! Shi Yan/Tian Jingyan/Shen Bai collaborated to prove that diabetes is associated with the risk of pancreatic cancer
Time of Update: 2022-10-01
iNaturePancreatic cancer is one of the leading causes of cancer death worldwide and in China. Pancreatic cancer usually has a worse prognosis than most other tumors, with a 5-year survival rate of les
-
Good drugs first, drug-resistant worry-free ositinib first-line treatment of drug resistance-histological transformation coping strategies
Time of Update: 2022-10-01
[3,4[1,2,5Figure 2: Current status of domestic and foreign guidelines for first-line treatment of oxitinibHistology transformation isImportant mechanisms of EGFR-TKI resistanceThere is no doubt that oxitinib as a first-line therapy for patients with advanced NSCLC with EGFR mutation positive can maximize the survival time of patients and highlight the clinical value of targeted therapy.
-
Researchers propose a predictive method for predicting the efficacy of neoadjuvant chemotherapy for advanced gastric cancer
Time of Update: 2022-10-01
Gastric cancer is a common malignant tumor originating from the epithelial epithelium of the gastric mucosa, its early symptoms are insidious and non-specific, often similar to the symptoms of chronic
-
Professor Fan Xinrong: NHT is booming, mHSPC combination therapy is charging again
Time of Update: 2022-10-01
Professor Fan Xinrong said that as early as 2015, CHAARTED, STAMPEDE and other trials found that compared with ADT treatment alone, the chemotherapy drug docetaxel combined with ADT treatment can significantly improve the overall prognosis of patients with high tumor load and prolong the survival of mHSPC patients.
-
2022 ESMO Global Perspectives Prof. Siow Ming Lee: Immunologic monotherapy can also bring survival benefits to patients with poor NSCLC
Time of Update: 2022-10-01
New advances or changes in clinical practice: Immunological monodrugs improve the survival of the elderly population and ensure a better quality of lifeThis year, our team presented the results of a Phase III IPSOS study at ESMO that showed that altilizumab monotherapy improves overall survival (OS) in patients with poor NSCLC, predominantly older adults, regardless of physical status or PD-L1 expression.
